Form 4: Cullinan Therapeutics CSO Sells Shares Under 10b5-1 Plan

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 1,780 shares of common stock at a weighted average price of $14.14, executed under a pre-established 10b5-1 trading plan.

Summary

• Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, Inc. (CGEM), reported a sale of common stock.
• The transaction involved 1,780 shares of common stock.
• The shares were sold at a weighted average price of $14.14 per share, with prices ranging from $13.89 to $14.35.
• The sale was executed on February 25, 2026, pursuant to a Rule 10b5-1 trading plan established on August 7, 2025.
• Following this transaction, Jennifer Michaelson beneficially owns 174,844 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is part of a pre-established 10b5-1 plan, which typically indicates planned liquidity or diversification rather than a change in sentiment regarding the company's future performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a Rule 10b5-1 plan, are common for executives managing personal finances and diversifying portfolios. Such pre-scheduled sales are generally viewed as less indicative of management's sentiment about the company's immediate prospects compared to unscheduled, open-market sales.

Related Party Transactions

• Jennifer Michaelson, Chief Scientific Officer, sold shares of Cullinan Therapeutics, Inc. common stock, which constitutes an insider transaction.

Stakeholder Impact

• Shareholders may observe a slight reduction in insider ownership, though the pre-scheduled nature of the sale under a 10b5-1 plan mitigates concerns about management's confidence.

Key Dates

Recommendation

The insider sale was conducted under a pre-established 10b5-1 plan, which suggests a planned financial event rather than a reaction to new company-specific information. This type of transaction typically does not signal a change in the company's fundamental outlook, thus a 'hold' recommendation is appropriate as it doesn't provide new information to alter an existing investment thesis.

Keywords

Cullinan Therapeutics, CGEM, Jennifer Michaelson, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Scientific Officer, Biotechnology